Gain Therapeutics Inc - GANX STOCK NEWS

Gain Therapeutics, Inc. (Nasdaq: GANX) announced the publication of preclinical data identifying a novel class of small molecule allosteric regulators with therapeutic potential for galactosidase beta 1 (GLB1)-related lysosomal storage disorders, including GM1 gangliosidosis. The study was published in PLOS ONE and demonstrated the potential of allosteric modulators as a therapeutic option for hard-to-treat genetic diseases where there are no effective approaches for disease modification.

Gain Therapeutics, Inc. (Nasdaq: GANX) announced that CEO Matthias Alder will participate in a panel at the AI Driven Drug Discovery Summit on December 6, 2023. The event will focus on collaboration in AI-driven drug discovery.

Gain Therapeutics, Inc. (Gain) (Nasdaq: GANX) closed an underwritten public offering of 2,545,000 shares of common stock and warrants to purchase up to 1,272,500 shares at a combined public offering price of $2.005 per share and accompanying warrant. In a private placement, Gain issued 2,500,088 shares of common stock and warrants to purchase up to 2,500,088 shares at an offering price of $2.00 per share. The gross proceeds from the offerings were approximately $10.1 million, excluding underwriting and placement agent discounts and commissions and other offering-related expenses. Gain intends to use the net proceeds for the development of its lead product candidate GT-02287 for the treatment of neurodegenerative diseases and for general corporate purposes.

Gain Therapeutics, Inc. (GANX) announced the pricing of an underwritten public offering of 2,213,044 shares of its common stock and warrants to purchase up to an aggregate of 1,106,522 shares of its common stock at a combined public offering price of $2.005 per share and accompanying warrant. The public offering price for each set of two shares of common stock and accompanying warrant to purchase one share of common stock is $4.01 per set of securities, yielding an effective price of $2.00 per share and $0.01 per warrant. The warrants are being sold at the rate of one warrant for every two shares of common stock. The warrants will have an exercise price of $2.75 per share, are exercisable immediately upon issuance, and will expire five years following the date of issuance. In connection with the offering, Gain has granted the underwriters a 30-day option to purchase up to an additional 15% of shares of common stock and/or warrants to purchase shares of common stock at the public offering price, less underwriting discounts and commissions. In a private placement to be completed concurrently with the completion of the public offering, Gain will issue to an accredited investor an aggregate of 2,500,088 shares of common stock (or pre-funded warrants in lieu thereof) and warrants to purchase up to 2,500,088 shares of common stock. The offering price per share and accompanying warrant sold in the private placement is $2.00. The warrants issued in the private placement will be exercisable at an exercise price of $2.75 per share, will be exercisable beginning six months after issuance and will expire five years from the date of issuance. Newbridge Securities Corporation is acting as the sole book-running manager for the public offering and as placement agent for the private placement. Allele Capital Partners, LLC is acting as Financial Advisor to Gain. Gain expects to receive aggregate gross proceeds from the public and private offering, excluding the exercise of the underwriters’ option, if any, of approximately $9.4 million, excluding underwriting and placement agent discounts and commissions and other offering-related expenses. The offerings are expected to close on or before November 28, 2023.

Gain Therapeutics, Inc. (Nasdaq: GANX) Proposes Public Offering to Fund Neurodegenerative Disease Treatment Development. Gain Therapeutics, Inc. announced a proposed public offering of its common stock and warrants to fund the development of its lead product candidate GT-02287 for the treatment of neurodegenerative diseases, including GBA1 Parkinson’s disease. The offering is subject to market conditions, and the company expects to use the net proceeds for clinical and nonclinical development as well as general corporate purposes.

Gain Therapeutics, Inc. (Nasdaq: GANX) initiates Phase 1 clinical study of GT-02287, with dosing escalation on schedule. The company also presented compelling preclinical data at the International Congress of Parkinson’s Disease and Movement Disorders and announced financial results for the third quarter of 2023, highlighting recent corporate progress.

Gain Therapeutics announces dosing of first two subjects in Phase 1 clinical trial for GT-02287, its lead drug candidate for GBA1 Parkinson's disease

Gain Therapeutics CEO to participate in Cantor Fitzgerald Global Healthcare Conference

Gain Therapeutics CEO to present at Neurodegeneration Targets Conference